Painful Diabetic Peripheral Neuropathy (PDPN)
Conditions
Keywords
Painful Diabetic Peripheral Neuropathy, Qutenza
Brief summary
The purpose of the study is to assess the safety of repeated applications of QUTENZA in reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.
Detailed description
Patients will be divided into 3 groups of approximately equal size. In the first group, patients will receive a QUTENZA patch applied for 30 minutes to the feet; in the second group, patients will receive a QUTENZA patch applied for 60 minutes to the feet. In both these groups patients will also continue to receive their normal treatment (Standard of Care (SOC)) for their peripheral neuropathic pain (PNP) and may receive further QUTENZA patch applications in the same way during the study. The third group will not receive a QUTENZA patch but will continue to receive their normal treatment for their neuropathic pain (SOC). Subjects will be involved in the study for up to 15 months and will have to visit the clinic at least 9 times.
Interventions
DRUGQUTENZA
A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to diabetes * Stable glycemic control for at least 6 months prior to screening visit * Average Numeric Pain Rating Scale (NPRS) score over the last 24 hours of \>4 at the screening and the baseline visit
Exclusion criteria
* Primary pain associated with PDPN in the ankles or above * Pain that could not be clearly differentiated from, or conditions that might interfere with, the assessment of PDPN * Significant pain (moderate or above) of an etiology other than PDPN, that may interfere with judging PDPN-related pain * Female subjects of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain highly effective birth control during the study. * Hypersensitivity to capsaicin (i.e., chili peppers or over-the-counter \[OTC\] capsaicin products), any QUTENZA excipients, Eutectic Mixture of Local Anesthetics( EMLA) ingredients or adhesives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale | Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability of patch application by dermal assessment | Screening till Last visit when QUTENZA patch is applied (up to 53 weeks) | — |
| Tolerability of patch application by pain now Numeric Pain Rating Scale (NPRS) scores after patch application | Baseline till Last visit when QUTENZA patch is applied (up to 52 weeks) | Assessed within 15 minutes and 60 minutes after patch removal. |
| Tolerability of patch application by rescue medication use | Days 1 through 5 after each patch application | — |
| Adverse Events and serious adverse Events | Screening visit through End of study visit (up to 65 weeks) | — |
| Vital Signs (heart rate and blood pressure) | Screening visit through End of study visit (up to 65 weeks) | In case of patch application to be performed within 15 minutes before topical anesthetic application and within 15 minutes after patch removal. |
| Neurological function as assessed by the Utah Early Neuropathy Scale (UENS) and sensory testing | Baseline till End of Study (up to 64 weeks) | Physicians measuring neurological function will be blinded to treatment |
| Intensity of neuropathic pain using average pain NPRS scores | Screening visit through End of study visit (up to 65 weeks) | Question 5 of Brief Pain Inventory-Diabetic Neuropathy (BPI-DN) |
| Generic HRQOL measured by European Quality of Life - 5 Dimensions (EQ-5D) questionnaire | After each patch application, from first patch application through End of Study (up to 64 weeks) | — |
| Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit | End of Study (up to 65 weeks) | — |
| Brief Pain Inventory (BPI) pain severity index and pain interference index | Screening visit through End of study visit (up to 65 weeks) | — |
| Patient Global Impression of Change | After each patch re-application, from first patch re-application through End of Study visit (up to 56 weeks) | — |
| Laboratory Analyses | Screening visit through End of study visit (up to 65 weeks) | The tests performed at the screening visit will include Hematology: Red Blood Cell Count, White Blood Cell Count, Lymphocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Hemoglobin, Hematocrit and Platelets. Biochemistry: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT), Alkaline Phosphatase, Sodium, Potassium, Blood Urea Nitrogen (BUN), Creatinine and Lipid profile. Subsequent HbA1c and lipid profile follow-up will be done at bi-monthly visits. The other tests will be performed if clinically indicated. |
Countries
Belgium, Czechia, France, Germany, Italy, Netherlands, Poland, Russia, Spain, Ukraine, United Kingdom
Outcome results
None listed